Evidence map›Paper›PMID 34002291›Full record

ArticlePediatric nephrology (Berlin, Germany)2021

Fenoldopam and renal hemodynamics in shiga toxin-related hemolytic uremic syndrome.

Gianluigi Ardissino, Antenore Giussani, Valentina Capone, Sara Testa, Cristiano Gandini, Giovanni Montini, ItalKid-HUS Network

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gianluigi ArdissinoCenter for HUS Prevention Control and Management at the Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via della Commenda 9, 20122, Milano, Italy. ardissino@centroseu.org.ORCID 0000-0002-0659-1206
Antenore GiussaniKidney Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
Valentina CaponeCenter for HUS Prevention Control and Management at the Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via della Commenda 9, 20122, Milano, Italy.
Sara TestaCenter for HUS Prevention Control and Management at the Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via della Commenda 9, 20122, Milano, Italy.
Cristiano GandiniPediatric Intensive Care Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
Giovanni MontiniCenter for HUS Prevention Control and Management at the Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via della Commenda 9, 20122, Milano, Italy.
ItalKid-HUS Network

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFenoldopam, a vasodilating agent, may represent a potential therapeutic opportunity to increase renal perfusion in those conditions where renal hemodynamics are severely impaired by vascular sub-occlusion, as, indeed, is the case in thrombotic microangiopathies.

methodsThe renal resistance index (RRI) was measured, on and off fenoldopam, in 27 children with STEC-HUS.

resultsA 12% decrease in RRI was observed on fenoldopam compared to off treatment without changes in the systemic hemodynamics and with no side effects.

conclusionsIf confirmed in larger series, fenoldopam may become an important addition to supportive care to reduce ischemic damage in STEC-HUS and improve long-term outcomes.

Indexed as

Escherichia coli InfectionsHemolytic-Uremic SyndromeShiga-Toxigenic Escherichia coliChildFenoldopamHemodynamicsHumansShiga ToxinFenoldopamShiga ToxinChildrenFenoldopamHemolytic uremic syndromeRenal hemodynamicsRenal resistance indexThrombotic microangiopathy

Identifiers

PMID34002291

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.